HGH Fragment - Beligas Pharmaceuticals

Originally researched in the 1970s, HGH Fragment 176-191 showed promise as a fat-loss agent. While development slowed in the early 1980s, it was later studied for its potential to reduce fat specifically without raising growth hormone levels. Though not yet FDA-approved, HGH Fragment 176-191 is sold as a research peptide and is widely available on the gray market, where users seek its lipolytic effects in their weight-management programs​.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about HGH Fragment by Beligas Pharmaceuticals, consult with your doctor or healthcare professional.